Liu B, Ren KK, Wang N, Xu XP, Wu J. Timing of convalescent plasma therapy-tips from curing a 100-year-old COVID-19 patient using convalescent plasma treatment: A case report . World J Clin Cases 2021; 9(12): 2890-2898 [PMID: 33969074 DOI: 10.12998/wjcc.v9.i12.2890]
Corresponding Author of This Article
Jue Wu, PhD, Chief Physician, Translational Medicine Research Center, Medical Innovation Research Division of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. juetwmj79347@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jue Wu, Translational Medicine Research Center, Medical Innovation Research Division of Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Liu B collected the data for the case presentation and contributed to manuscript drafting; Wu J and Wang N contributed to supervision of the data collection, analysis of the data, and write-up of this manuscript; Ren KK and Xu XP contributed to the data analysis; All authors contributed to the critical review and final approval of the manuscript.
Supported byMedical Collaborative Science and Technology Innovation Research Project of Science and Technology Commission of Beijing, No. Z181100001918013; and Nanchang Science and Technology Bureau, No. 20203306.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jue Wu, PhD, Chief Physician, Translational Medicine Research Center, Medical Innovation Research Division of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. juetwmj79347@163.com
Received: December 5, 2020 Peer-review started: December 5, 2020 First decision: January 7, 2021 Revised: January 18, 2021 Accepted: March 3, 2021 Article in press: March 3, 2021 Published online: April 26, 2021
Abstract
BACKGROUND
Convalescent plasma therapy is used for the treatment of critically ill patients for newly discovered infectious diseases, such as coronavirus disease 2019 (COVID-19) pneumonia, under the premise of lacking specific treatment drugs and corresponding vaccines. But the best timing application of plasma therapy and whether it is effective by antiviral and antibiotic treatment remain unclear.
CASE SUMMARY
We describe a patient with COVID-19, a 100-year-old, high-risk, elderly male who had multiple underlying diseases such as stage 2 hypertension (very high-risk group) and infectious pneumonia accompanied by chronic obstructive pulmonary disease and emphysema. We mainly describe the diagnosis, clinical process, and treatment of the patient, including the processes of two plasma transfusion treatments.
CONCLUSION
This provides a reference for choosing the best timing of convalescent plasma treatment and highlights the effectiveness of the clinical strategy of plasma treatment in the recovery period of patients with COVID-19 pneumonia.
Core Tip: A 100-year-old coronavirus disease 2019 (COVID-19) patient with several underlying diseases including hypertension (stage 2 hypertension) accompanied by chronic obstructive pulmonary disease and emphysema was treated using convalescent plasma. Besides the effective maintenance of supportive treatment and no antiviral and antibiotic treatment, the convalescent plasma was infused into the patient in the early stage of the infection. This choice of time points (days 7 and 11 of hospitalization) provides a reference for choosing the best timing of convalescent plasma treatment and highlights the effectiveness of the clinical strategy of plasma treatment in the recovery period of patients with COVID-19 pneumonia.
